Please assess the completion status of the following clinical trial:

Trial Title: Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Voluntarily written informed consent~* Age: between 18 and 75 years (both inclusive).~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 1. Cohort of patients with SCLC and endometrial cáncer ECOG PS ≤ 2.~* Life expectancy ≥ 3 months.~* Patients with a histologically/cytologically confirmed diagnosis of advanced disease of any of the following tumors:~  1. Breast cancer~ 2. Soft-tissue sarcoma~ 3. Primary bone sarcomas.~ 4. Gynecologic tumors (endometrial adenocarcinomas, epithelial ovarian cancer...)~ 5. Hepatocellular carcinoma~ 6. Gastroenteropancreatic neuroendocrine tumors~ 7. Small cell lung cancer (SCLC)~ 8. Gastric cancer~ 9. Bladder cancer~ 10. Adenocarcinoma of unknown primary site~* At least three weeks since the last anticancer therapy, including radiotherapy~* Adequate bone marrow, renal, hepatic, and metabolic function~* Left ventricular ejection fraction (LVEF) by echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan within normal range (according to institutional standards).~* Women of childbearing potential must have a negative serum pregnancy test before study entry. Both women and men must agree to use a medically acceptable method of contraception throughout the treatment period and for six weeks after discontinuation of treatment~Exclusion Criteria:~* Concomitant diseases/conditions:~  * History or presence of unstable angina, myocardial infarction, congestive heart failure, or clinically significant valvular heart disease within last year.~ * Symptomatic or any uncontrolled arrhythmia~ * Ongoing chronic alcohol consumption, or cirrhosis~ * Active uncontrolled infection.~ * Known human immunodeficiency virus (HIV) infection.~ * Any other major illness that, in the Investigator's judgment~* Brain metastases or leptomeningeal disease involvement.~* Men or women of childbearing potential who are not using an effective method of contraception~* Patients who have had radiation therapy in more than 35% of the bone marrow. This criterion will not apply to cohort of patients with SCLC and endometrial cáncer.~* History of previous bone marrow and/or stem cell transplantation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- lurbinectedin (PM01183) / doxorubicin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).